The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Meiji Pharma to Discontinue Sales of Abilify Generics
October 30, 2024
- Astellas Recalls Some Batches of Betanis over Nitrosamine Impurities
October 30, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Xocova Makes Mark in PIII Study for Post-Exposure Prophylaxis: Shionogi
October 30, 2024
- Amitiza Tops Drug Promotion Rankings for 5 Channels in September: Intage
October 30, 2024
- Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
October 29, 2024
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
- Astellas Pulls EU Filing for Geographic Atrophy Drug
October 29, 2024
- Astellas Drastically Shaving Research Time with AI Drug Discovery
October 28, 2024
- AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
- Novo Inks Collab Pact with Kasugai City on Obesity Measures
October 25, 2024
- Shionogi-Ube’s Anti-RSV Drug Gets Fast-Track Tag in US
October 25, 2024
- Misako Hamamura to Head Up Alexion Japan from Next Year
October 25, 2024
- Guardant to Close Japan Lab Due to Sluggish Product Uptake
October 24, 2024
- NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
- Otsuka’s IgA Nephropathy Drug Makes Mark in PIII, Eyes Accelerated Path
October 23, 2024
- Tirzepatide Cuts Body Weight in Japanese Adults with Obesity: PIII
October 23, 2024
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…